543500 — Evoq Remedies Income Statement
0.000.00%
Last trade - 00:00- IN₹46.31m
- IN₹46.99m
- IN₹255.07m
Annual income statement for Evoq Remedies, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Preliminary |
| Revenue | |||||
| Total Revenue | 168 | 204 | 40.5 | 118 | 255 |
| Cost of Revenue | |||||
| Gross Profit | 30.1 | 10.6 | 25 | -13.2 | 0.318 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 153 | 241 | 57 | 140 | 270 |
| Operating Profit | 14.6 | -37.4 | -16.4 | -22.9 | -15 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 14.6 | 22.8 | 6.11 | 1.28 | -2.51 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 10.9 | 16.2 | 4.52 | 0.882 | -2.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 10.9 | 16.2 | 4.52 | 0.882 | -2.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 10.9 | 16.2 | 4.52 | 0.882 | -2.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.802 | 1.19 | 0.333 | 0.035 | -0.1 |
| Dividends per Share |